RTI introduces next generation of BioCleanse, restructures agreement with MSD.Regeneration Technologies, Inc. (RTI RTI - Return from interrupt ), Alachua, FL announced it has introduced the next-generation of its BioCleanse tissue sterilization system. The company says the new system sterilizes tissue from a single donor in one of several individual processing units, thus eliminating the need to batch tissue from multiple donors during the sterilization process. The BioCleanse system is a low temperature chemical sterilization process that eliminates bacteria, fungi and spores, as well as enveloped and non-enveloped viruses such as HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and hepatitis from tissue, without altering the strength or biocompatibility biocompatibility the quality of not having toxic or injurious effects on biological systems. biocompatibility 1. The extent to which a foreign, usually implanted, material elicits an immune or other response in a recipient 2. of the allograft allograft: see transplantation, medical. , RTI says. Earlier this year the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. completed a compliance review of the process and determined that RTI had successfully validated the process. (Transplant News, February 27, 2002) RTI also announced it has agreed to new terms with Medtronic Sofamor Danek (MSD) for an exclusive license and distribution agreement to supply human allograft tissue and bone paste for spine surgery. MSD will continue to serve as exclusive worldwide distributor for specialty tissue allografts allografts (al´  graf´ts),n.pl the transplantation of tissue between genetically nonidentical individuals of the same species. and bone paste processed by RTI for use in spinal surgery. Under the new agreement, the companies have agreed to co-develop new tissue-based spine surgery solutions and restructure financial terms to reflect the value of RTI's proprietary technology including its BioCleanse process. Contact: Quenta Vettel - (386) 318-8888 |
|
||||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion